Why is CRISPR falling?

Could you please explain the reasons behind the decline in CRISPR's value? Is it due to concerns over its efficacy, safety, or competition from other gene-editing technologies? Or is there a broader market trend affecting biotechnology stocks that's impacting CRISPR's performance? I'd appreciate any insights you have on this matter and how investors should approach CRISPR in light of its current situation.